REBIF


Also found in: Medical.
AcronymDefinition
REBIFREcombinant Beta InterFeron (Serono Group multiple sclerosis treatment)
References in periodicals archive ?
The positive CHMP opinion is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS.
and Britain comparing high- and low-dose Campath to Rebif in 400 people with early relapsing-remitting MS.
The randomised phase III CARE-MS II (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis) trial compared investigational MS treatment alemtuzumab to approved interferon beta-1a in 840 patients with relapsing-remitting multiple sclerosis (RRMS).
an estimated 65 percent of alemtuzumab-treated patients were free of clinically-active disease, compared to 27 percent of patients taking Rebif (p<0.
In the CARE-MS I trial, two annual cycles of alemtuzumab treatment resulted in a 55% reduction in relapse rate compared to Rebif over the two years of the study, hence satisfying the first primary endpoint and therefore meeting the predefined protocol criteria for declaring the study a success.
The company said that in the CARE-MS I trial two annual cycles of alemtuzumab treatment resulted in a 55% reduction in relapse rate compared to Rebif over the two years of the study (p
Since the results from the PRISMS trial were first announced in 1997, Rebif has been prescribed for MS in over 60 countries worldwide.
CARE-MS II, which also compares alemtuzumab to Rebif, is studying RRMS patients who relapsed while on other MS therapies.
Contract award: delivery of drugs - avonex - l03ab07, esbriet - l04ax05, herceptin 150 mg - l01xc03, rebif - l03ab07, sutent - l01xe04, tarceva - l01xe03.
The CAMMS223 Phase 2 trial, first reported in the New England Journal of Medicine in 2008, compared alemtuzumab to the approved MS therapy Rebif (high dose interferon beta-1a) in early, active, relapsing-remitting multiple sclerosis (RRMS) patients who had received no prior therapy.
Avonex and Rebif (both interferon beta-1a) should be refrigerated, but can be stored at 77[degrees] Fahrenheit for up to 30 days.
Over the last few years, the MS market has been driven by five disease-modifying agents: Tevas Copaxone (glatiramer acetate), Biogen Idecs Avonex (interferon beta-1a) and Tysabri (natalizumab), Merck KGaAs Rebif (interferon beta-1a) and Bayers Betaferon (interferon beta-1b).